The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 11-12, 2013, Pages 1365-1372

  Maasoumy, B ^a   Port, K ^a   Calle Serrano, B ^a   Markova, A A ^a   Sollik, L ^a   Manns, M P ^a   Cornberg, M ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS;

EID: 84893701238     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12523     Document Type: Article

References (26)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
2. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-12.
3. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.e1.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
5. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-37.
6. Wedemeyer H. Hepatitis C in 2012: on the fast track towards IFN-free therapy for hepatitis C? Nat Rev Gastroenterol Hepatol 2013; 10: 76-8.
7. Rowe IA, Houlihan DD, Mutimer DJ. Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Aliment Pharmacol Ther 2012; 36: 670-9.
8. Maasoumy B, Manns MP. Optimal treatment with boceprevir for chronic HCV infection. Liver Int 2013; 33 (Suppl 1): 14-22.
9. Jesudian AB, Jacobson IM. Optimal treatment with telaprevir for chronic HCV infection. Liver Int 2013; 33 (Suppl 1): 3-13.
10. Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-62.
11. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
12. Joshi D, Carey I, Agarwal K. Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients. Aliment Pharmacol Ther 2013; 37: 659-71.
13. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic) - nct01514890. J Hepatol 2013; 59: 434-41.
14. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013; 58: 792-800.
15. Kiser JJ, Burton JRJ. Everson GT. Nat Rev Gastroenterol Hepatol: Drug-drug interactions during antiviral therapy for chronic hepatitis C, 2013.
16. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 2009; 5: 26-34.
17. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
18. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60: 1139-51.
19. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006; 40: 753-7.
20. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy 2009; 29: 1386-91.
21. Hoover WC, Britton LJ, Gardner J, Jackson T, Gutierrez H. Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. Ann Pharmacother 2011; 45: e38.
22. Hugen PW, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000; 34: 465-70.
23. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-70.
24. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS- 7977) and the immunosuppressants cyclosporine A or tacrolimus in healthy volunteers. Hepatology 2012; 56 (Supplement): 1063A.
25. Kirby B, Mathias A, Rossi S, Moyer C, Shen G, Kearney BP. No clinically significant pharmacokinetic drug interaction between sofosbuvir (GS- 7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. Hepatology 2012; 56(Supplement): 1067A.
26. Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013; 12: 595-610.